NCT03604978 2026-03-18
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT04189172 2026-03-18
MiDura
Aesculap AG
Active not recruiting
NCT07476404 2026-03-17
GM-HES
Chiang Mai University
Completed
NCT05940493 2026-03-13
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2 Recruiting
NCT00598351 2026-03-11
Natural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03971461 2026-03-11
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
Phase 2 Active not recruiting
NCT06104930 2026-03-10
MOLI
University Hospital Heidelberg
Phase NA Recruiting
NCT05425004 2026-03-05
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Phase 2 Recruiting
NCT02523014 2026-03-04
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT04298541 2026-02-27
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Phase 2 Not yet recruiting
NCT06377371 2026-02-27
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Weill Medical College of Cornell University
Phase 4 Recruiting
NCT07428616 2026-02-24
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Not yet recruiting
NCT07428213 2026-02-23
PIVIM
Hospices Civils de Lyon
Phase NA Not yet recruiting
NCT06878469 2026-02-19
SIMPLIF-AI
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase NA Recruiting
NCT07418775 2026-02-18
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
University of California, San Francisco
Not yet recruiting